What is Science?
Science Corporation operates as a clinical-stage medical technology enterprise dedicated to the advancement of neural interface and neuro-engineering solutions. The company's core mission centers on the development of sophisticated biohybrid devices designed to restore critical human functions, including vision, cognition, and mobility, for individuals suffering from severe neurological conditions. By integrating research, clinical trials, and proprietary manufacturing capabilities, the firm maintains a unique market position that allows it to translate laboratory-based innovations into scalable, patient-centric medical applications. Its focus on high-impact health outcomes distinguishes it within the competitive landscape of biotechnology and neuro-technology, where the convergence of hardware and biological systems remains a primary frontier for medical innovation.
How much funding has Science raised?
Science has raised a total of $230M across 1 funding round:
Series C
$230M
Series C (2026): $230M with participation from In-Q-Tel, Quiet Capital, Lightspeed Venture Partners, Y Combinator, and Khosla Ventures
Key Investors in Science
In-Q-Tel
In-Q-Tel is a strategic investment firm serving as the venture arm for the U.S. national security community, focusing on high-impact technologies in biotech and AI.
Quiet Capital
Quiet Capital is a founder-led venture firm that provides patient capital and deep operational expertise to support impactful companies across the health and industrial sectors.
Lightspeed Venture Partners
Lightspeed Venture Partners is a global multi-stage firm that partners with founders from seed through IPO, specializing in enterprise software and infrastructure.
What's next for Science?
With the successful closure of this latest funding round, Science Corporation is poised to accelerate its clinical development pipeline and expand its operational capacity. The strategic focus will likely shift toward optimizing its biohybrid neural interfaces for broader clinical utility and strengthening its regulatory pathways. As the company continues to mature, the integration of its research-to-patient infrastructure will be critical in maintaining its competitive edge. Investors are closely monitoring the firm's ability to translate its neuro-engineering breakthroughs into standardized medical treatments, a milestone that would represent a significant advancement in the treatment of neurological disorders and solidify the company's role as a leader in the next generation of human-machine interface technology.
See full Science company page
